

LETTER TO THE EDITOR

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis

Blood Cancer Journal (2017) 7, e584; doi:10.1038/bcj.2017.66;
published online 21 July 2017

Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap

syndrome characterized by peripheral blood monocytosis (absolute monocyte count/AMC $\geq 1 \times 10^9/l$, $\geq 10\%$ of the total white blood cell count) and an inherent risk for leukemic transformation.^{1,2} Monocytosis, however, is not pathognomeric for CMML and can be associated with reactive and clonal processes, including MPN such as polycythemia Vera (PV) and primary

Table 1. Clinical and laboratory features of patients with chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms (MPN) assessed for monocyte subset analysis by multiparametric flow cytometry

Variable	CMML(n = 15)	MPN (n = 11)	P-value
Age at diagnosis in years; median (range)	72 (61–79)	66 (38–77)	0.04
Gender (Male) n (%)	13 (87%)	7 (64%)	0.2
Hemoglobin, g/dl; median (range)	12.7 (6.7–15)	10.5 (6.9–4.8)	0.5
WBC $\times 10^9/l$; median (range)	12.7 (2.3–1477)	27.7 (5.6–95)	0.3
AMC $\times 10^9/l$; median (range)	3.3 (1.0–16.2)	2.6 (1.1–8.5)	0.5
Platelets $\times 10^9/l$; median (range)	81 (10–418)	153 (34–723)	0.04
Presence of circulating immature myeloid cells; n (%)	8 (53%)	8 (73%)	0.3
PB blast %; median (range)	0 (0–19)	0 (0–19)	0.4
BM blast %; median (range)	1 (0–19)	0 (0–10)	0.002
Karyotype Abnormal; (%)	4 (36%) (n = 11)	5 (50%) (n = 10)	0.5
<i>Targeted next generation sequencing results</i>			
<i>Epigenetic regulator genes</i>			
ASXL1	4 (36%) (n = 11)	2 (66%) (n = 3)	0.3
TET2	11 (100%) (n = 11)	0 (n = 3)	0.0002
DNMT3A	2 (18%) (n = 11)	0 (n = 3)	
EZH2	2 (18%) (n = 11)	0 (n = 3)	0.4
<i>Spliceosome components</i>			
SRSF2	5 (45%) (n = 11)	2 (66%) (n = 3)	0.4
SF3B1	0 (n = 11)	1 (33%) (n = 3)	0.5
U2AF1	1 (9%) (n = 11)	0 (n = 3)	0.05
ZRSR2	1 (9%) (n = 11)	0 (n = 3)	0.6
<i>Signaling genes</i>			
JAK2V617F	1 (9%) (n = 11)	6 (60%) (n = 10)	0.6
CALR	0 (n = 11)	2 (29%) (n = 7)	0.05
MPL	0 (n = 12)	1 (20%) (n = 5)	0.06
NRAS	0 (n = 11)	1 (33%) (n = 3)	0.1
KRAS	0 (n = 11)	0 (n = 3)	0.05
PTPN11	1 (9%) (n = 11)	0 (n = 3)	0.6
CSF3R	0 (n = 11)	1 (33%) (n = 3)	0.05
CBL	0 (n = 11)	0 (n = 3)	-
<i>Transcription factor</i>			
RUNX1	0 (n = 11)	0 (n = 3)	-
<i>Others</i>			
P53	1 (9%) (n = 11)	0 (n = 3)	0.6
PHF6	1 (9%) (n = 11)	0 (n = 3)	0.6
SETBP1	0 (n = 11)	0 (n = 3)	-
Leukemic Transformation; n (%)	2 (13%)	1 (9%)	< 0.001
Deaths; n (%)	4 (27%)	1 (9%)	

Abbreviations: AMC, absolute monocyte count; BM, bone marrow; CMML, chronic myelomonocytic leukemia; MPN, myeloproliferative neoplasm; PB, peripheral blood; WBC, white blood cell count. Bold values are represent P values that have reached statistical significance ($P < 0.05$).




Figure 1. (a) Monocyte subset analysis by multiparametric flow cytometry demonstrating monocyte repartitioning with a MO1 fraction of 94.46% in a patient with chronic myelomonocytic leukemia. (b) Monocyte subset analysis by multiparametric flow cytometry demonstrating a normal monocyte distribution pattern in a patient with primary myelofibrosis and absolute moncytosis.

myelofibrosis (PMF).^{3–5} On the basis of the flow cytometric expression of CD14/CD16, monocytes can be classified into; classical MO1 ($CD14^+/CD16^-$), intermediate MO2 ($CD14^+/CD16^+$) and non-classical MO3 ($CD14^-/CD16^+$) fractions, with MO1 constituting the major monocyte population (85%) in healthy conditions.⁶ A recent publication using multiparametric flow cytometry demonstrated a characteristic increase in classical monocytes (cut off value 94%) in CMML patients, distinguishing them from other causes of reactive and clonal moncytosis.⁶ The associated sensitivity and specificity values were 95.1% and 90.6%, respectively. This pattern was independent of mutational background and CMML patients that responded to hypomethylating agents had normalization of the MO1 fraction, thus potentially acting as a biomarker predicting response. These findings were validated by a second study, where MO1 monocytes were also found to define a favorable subset of MDS patients, characterized by a higher prevalence of *SF3B1* mutations.⁷ Given the inherent difficulty in distinguishing CMML cases from MPN cases with absolute moncytosis, we carried out this study using a similar multiparametric flow cytometry approach.

We prospectively evaluated 15 consecutive, treatment naïve ($n=12$) and previously treated but now relapsed ($n=3$), patients with WHO defined CMML and 11 treatment naïve patients with MPN and an AMC $\geq 1 \times 10(9)/l$ (PMF-8, PV-2, chronic neutrophilic leukemia-1). All diagnoses were based on the 2016 WHO criteria for CMML and MPN.¹ Targeted exome sequencing and multiparametric flow cytometry were carried out on peripheral blood samples using previously described methods.^{6,8} In addition, 26 age-matched controls and two cases each with *BCR-ABL1* defined chronic myeloid leukemia and MDS/MPN- unclassifiable (U) with AMC $> 1 \times 10(9)/l$ were included as controls. Clinical and laboratory characteristics, including targeted exome sequencing results are outlined in Table 1. In comparison to MPN patients with moncytosis, those with CMML were older ($P=0.04$), had lower platelet counts ($P=0.04$), had higher BM blast % ($P=0.002$) and had a higher frequency of *TET2* mutations ($P=0.0002$). There were no *CALR*, *MPL*, *SF3B1* and *CSF3R* mutations seen in CMML patients. In the CMML group, at last follow up (median follow up 16 months), 2 (13%) leukemic transformation and 4 (27%) deaths were documented. In total 14 (93%) of 15 CMML patients had a MO1 fraction $\geq 94\%$ (mean 95.6%), while one patient with a *TET2/SRSF2* co-mutated CMML had an MO1 fraction of 92%. This patient had concomitant polymyalgia rheumatica and had been on corticosteroid therapy at the time of testing. In contrast, all 11

(100%) MPN patients with moncytosis had a MO1 fraction $< 92\%$ (mean 77%) (Figures 1a and b). These findings resulted in a test sensitivity of 93.3%, specificity of 100%, positive predictive value of 100% and a negative predictive value of 91.7%. In addition monocyte partitioning was effective in differentiating CMML cases from age matched controls and from the two patients each with CML and MDS/MPN-U with absolute moncytosis.

Moncytosis can occur in patients with MPN, especially PV ($\approx 20\%$) and PMF ($\approx 15\%$), is associated with poor outcomes, and at diagnosis, can make it difficult to distinguish between MPN and CMML.^{4,5} This has important diagnostic, prognostic and therapeutic implications for affected patients. Our study successfully demonstrates the use of monocyte partitioning by multiparametric flow cytometry to distinguish CMML from MPN with moncytosis. This test when used in addition to bone marrow morphology and molecular studies will help improve our diagnostic accuracy. Given the high prevalence of autoimmune and inflammatory diseases in CMML ($\approx 30\%$), alterations in the MO2 fraction have been described, giving rise to false negative flow cytometry results.⁹ This subset of patients' needs further prospective evaluation.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

Current publication is supported in part by grants from the 'The Henry J. Predolin Foundation for Research in Leukemia, Mayo Clinic, Rochester, MN, USA'. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

MM Patnaik¹, MM Timm², R Vallapureddy¹, TL Lasho¹, RP Ketterling², N Gangat¹, M Shi², A Tefferi¹, E Solary³, KK Reichard² and D Jevremovic²

¹Division of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA

²Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, MN, USA and

³Department of Hematology, Institute Gustave Roussy, Paris, France

E-mail: Patnaik.mrinal@mayo.edu

REFERENCES

- 1 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; **127**: 2391–2405.
- 2 Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia* 2014; **28**: 2206–2212.
- 3 Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. *Am J Hematol* 2016; **91**: 631–642.
- 4 Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. *Leuk Res* 2007; **31**: 1503–1509.
- 5 Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C et al. Monocytosis in polycythemia vera: clinical and molecular correlates. *Am J Hematol* 2017; **92**: 640–645.
- 6 Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. *Blood* 2015; **125**: 3618–3626.
- 7 Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q et al. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. *Blood* 2017; **129**: 1881–1883.
- 8 Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. *Blood Cancer J* 2016; **6**: e385.
- 9 Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N et al. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leuk Lymphoma* 2017; **58**: 1488–1493.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017